Form 4: MDXG General Counsel Granted Equity Awards

MIMEDX GROUP's General Counsel and CAO, William Frank Hulse IV, was granted 74,987 restricted stock units and 62,758 stock options.

Summary

• William Frank Hulse IV, General Counsel and CAO of MIMEDX GROUP, INC. (MDXG), acquired 74,987 shares of common stock in the form of restricted stock units.
• These restricted stock units were granted on March 4, 2026, at a price of $0 per share, and will vest fully on the third anniversary of the grant date, subject to continued employment.
• Following this transaction, Mr. Hulse beneficially owns 488,536 shares of common stock.
• Mr. Hulse also acquired 62,758 stock options with an exercise price of $5.1 per share, granted on March 4, 2026, at a price of $0.
• These stock options will vest 25% on each anniversary of the grant date, subject to continued employment, and have an expiration date of March 3, 2033.
• Following this transaction, Mr. Hulse beneficially owns 171,190 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive for corporate governance and executive alignment, as it ties a key executive's compensation to the company's long-term performance, which is generally favorable for shareholders.

Positives

• The equity grants align the General Counsel's financial interests with the long-term performance and shareholder value of MIMEDX GROUP.
• The multi-year vesting schedules for both restricted stock and stock options serve as a retention mechanism for a key executive.

Negatives

• The grants are subject to continued employment, meaning the executive must remain with the company to realize the full value.
• The value of the stock options is dependent on the future stock price exceeding the exercise price of $5.1.

Risks

• The value of the restricted stock and stock options is subject to market fluctuations of MIMEDX GROUP's common stock.
• The vesting of both the restricted stock and stock options is contingent upon the reporting person's continued employment with the company.

Future Outlook

The restricted stock units are set to vest fully on the third anniversary of the grant date, while the stock options will vest 25% annually over four years, both contingent on the executive's continued employment.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock and stock options, are a standard component of executive compensation packages across various industries, including the medical device and biotech sectors. These grants are designed to incentivize long-term performance and align the interests of management with those of shareholders.

Comparison to Industry Standards

• StockSavvy.ai observes that multi-year vesting schedules for restricted stock and options, typically ranging from three to five years, are standard practice across industries, including medical technology, to promote long-term executive retention and performance.
• The grant of both restricted stock and stock options is a common dual-incentive approach, providing both a direct equity stake and upside potential, comparable to compensation structures seen at companies like Stryker Corporation or Medtronic plc for similar executive roles.

Stakeholder Impact

• Shareholders: The grants are intended to align the General Counsel's interests with shareholder value creation over the long term.
• Employees: No direct impact on general employees is indicated by this filing, but it reflects the company's executive compensation strategy.

Next Steps

• The restricted stock units will vest fully on March 4, 2029, subject to continued employment.
• The stock options will vest 25% annually on March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030, subject to continued employment.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to an executive, which is a standard compensation practice. It does not provide new operational or financial data that would alter an investment thesis, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

MIMEDX GROUP, MDXG, Form 4, insider transaction, equity grant, restricted stock, stock options, executive compensation, William Frank Hulse IV